困難梭狀芽孢桿菌傳染病（CDI）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 儘管患者數量相對穩定，但受新治療方法的引入推動，法國 CDI 市場預計將出現溫和成長，從 2025 年的 7800 萬美元成長到 2035 年的 1.17 億美元。
• 患者數量成長有限（年複合成長率為 0.4-0.5%），顯示市場擴張主要受以下因素驅動：
• 增加針對復發的先進治療方法的使用
• 逐步過渡到基於微生物組的治療和輔助性治療
• 目前市場收入主要由標準抗生素療法（例如萬古黴素、非達黴素）支撐，這些療法仍然是急性護理的基礎。
• 未來的成長將取決於創新治療方法的廣泛應用，這些療法專注於預防復發和改善長期療效，尤其是在高風險患者群體中。

困難梭狀芽孢桿菌傳染病（CDI）概述

困難梭狀芽孢桿菌傳染病（CDI）是由艱難梭菌引起的嚴重的毒素介導的胃腸道疾病。艱難梭菌是一種革蘭氏陽性、厭氧、產芽孢的細菌，主要在腸道菌叢因使用廣效抗生素而遭到破壞後定植於腸道。此疾病主要由高抗藥性芽孢的糞口傳播以及強效外毒素（特別是毒素A和B）的產生引起，這些毒素可導致上皮損傷、發炎和黏膜損傷。

臨床上，艱難梭菌感染的嚴重程度頻譜很大，從輕度至中度腹瀉到嚴重的危及生命的併發症，例如假膜性腸炎、中毒性巨結腸、腸穿孔和敗血症。它仍然是全球醫療相關感染的主要原因之一，對老年人、免疫力缺乏者和住院患者的影響尤其顯著。

艱難梭菌感染 (CDI) 的一個顯著特徵是其高復發率，這源於持續存在的孢子和治療後腸道菌群恢復不完全。這極大地影響了治療方法。雖然非達黴素和口服萬古黴素等標準抗生素仍是急性期治療的基礎，但治療策略正朝著預防復發的方向發展。這包括腸道菌叢重建療法，例如毒素中和單株抗體（如貝洛妥昔單抗）、糞便微生物移植 (FMT) 和新型生物製藥。這些療法旨在恢復定植抵抗力並降低復發風險。

主要亮點

• CDI 作為一種醫療保健相關感染疾病，給法國帶來了沉重的負擔，其中大多數病例發生在住院患者和老年人中。
• 預計法國住院的 CDI 病例數將從 2025 年的 63,000 例增加到 2035 年的 65,900 例，反映出人口老化和醫療保健接觸增加所導致的逐步成長（年複合成長率為 0.4%–0.5%）。
• 高復發率（20-30%）仍然是最重大的臨床挑戰，導致反覆住院和醫療負擔加重。
• 隨著人們對預防復發和恢復微生物群療法的關注度不斷提高，治療方法有望逐漸擺脫對傳統抗生素的依賴。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Acurx Pharmaceuticals Inc.
• Actelion
• Lumen Bioscience, Inc.
• AstraZeneca
• Crestone, Inc
• Vedanta Biosciences, Inc.
• Gateway Pharmaceutical LLC

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Clostridium Difficile Infection (CDI) Market Outlook

Thelansis's "Clostridium Difficile Infection (CDI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Clostridium Difficile Infection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Clostridium Difficile Infection (CDI) Overview

Clostridium difficile Infection (CDI) is a serious, toxin-mediated gastrointestinal disease caused by Clostridioides difficile, a Gram-positive, anaerobic, spore-forming bacterium that colonizes the gut following disruption of the normal intestinal microbiota-most commonly due to broad-spectrum antibiotic exposure. The disease is primarily driven by fecal-oral transmission of highly resilient spores and the production of potent exotoxins, notably Toxin A and Toxin B, which induce epithelial damage, inflammation, and mucosal injury.

Clinically, CDI presents across a wide severity spectrum, ranging from mild-to-moderate diarrhea to severe and life-threatening complications, including pseudomembranous colitis, Toxic Megacolon, bowel perforation, and sepsis. It remains a leading cause of healthcare-associated infections globally, particularly impacting elderly, immunocompromised, and hospitalized populations.

A defining characteristic of CDI is its high recurrence rate, driven by persistent spores and incomplete microbiome recovery following treatment. This has significantly shaped the therapeutic landscape. While standard-of-care antibiotics such as fidaxomicin and oral vancomycin remain the cornerstone for acute management, treatment strategies have evolved toward recurrence prevention. This includes toxin-neutralizing monoclonal antibodies (e.g., bezlotoxumab) and microbiome restoration approaches such as fecal microbiota transplantation (FMT) and emerging live biotherapeutic products, which aim to restore colonization resistance and reduce relapse risk.

Key Highlights

• CDI represents a significant healthcare-associated infection burden in France, with the majority of cases occurring in hospitalized and elderly populations.
• Hospitalized CDI cases in France are projected to increase from 63.0K in 2025 to 65.9K by 2035, reflecting a modest growth trajectory (0.4-0.5% CAGR) driven by aging population and healthcare exposure.
• High recurrence rates (20-30%) continue to be the most critical clinical challenge, contributing to repeated hospitalizations and increased healthcare burden.
• Growing focus on recurrence prevention and microbiome restoration therapies is expected to gradually shift treatment practices beyond conventional antibiotics.

Market Overview

• The France CDI market is projected to grow from $78M in 2025 to $117M by 2035, reflecting moderate growth driven by adoption of newer therapies despite a relatively stable patient base.
• Limited patient growth (0.4-0.5% CAGR) indicates that market expansion is primarily driven by:
• Increased use of premium therapies targeting recurrence
• Gradual shift toward microbiome-based and adjunctive treatments
• Current market revenues are largely driven by standard antibiotic therapies (e.g., vancomycin, fidaxomicin), which remain the backbone of acute treatment.
• Future growth will depend on the uptake of innovative therapies focused on reducing recurrence and improving long-term outcomes, particularly in high-risk patient populations.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Acurx Pharmaceuticals Inc.
• Actelion
• Lumen Bioscience, Inc.
• AstraZeneca
• Crestone, Inc
• Vedanta Biosciences, Inc.
• Gateway Pharmaceutical LLC

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)